Zymeworks (ZYME) Competitors $12.67 -0.21 (-1.62%) As of 09:52 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock ZYME vs. ZLAB, AKRO, MRUS, MOR, SRRK, PTGX, CRNX, SWTX, OGN, and CPRXShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include Zai Lab (ZLAB), Akero Therapeutics (AKRO), Merus (MRUS), MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Zai Lab Akero Therapeutics Merus MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals SpringWorks Therapeutics Organon & Co. Catalyst Pharmaceuticals Zymeworks (NYSE:ZYME) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, community ranking, earnings, analyst recommendations and dividends. Which has stronger valuation & earnings, ZYME or ZLAB? Zymeworks has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$76.30M11.54-$118.67M-$1.61-7.86Zai Lab$398.99M8.75-$334.62M-$2.59-12.24 Which has more risk & volatility, ZYME or ZLAB? Zymeworks has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Do analysts rate ZYME or ZLAB? Zymeworks presently has a consensus target price of $21.00, suggesting a potential upside of 65.94%. Zai Lab has a consensus target price of $47.37, suggesting a potential upside of 49.36%. Given Zymeworks' stronger consensus rating and higher possible upside, research analysts clearly believe Zymeworks is more favorable than Zai Lab.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Zai Lab 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the MarketBeat Community believe in ZYME or ZLAB? Zymeworks received 63 more outperform votes than Zai Lab when rated by MarketBeat users. Likewise, 67.74% of users gave Zymeworks an outperform vote while only 64.53% of users gave Zai Lab an outperform vote. CompanyUnderperformOutperformZymeworksOutperform Votes29467.74% Underperform Votes14032.26% Zai LabOutperform Votes23164.53% Underperform Votes12735.47% Do insiders and institutionals hold more shares of ZYME or ZLAB? 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 1.9% of Zymeworks shares are held by insiders. Comparatively, 13.9% of Zai Lab shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to ZYME or ZLAB? In the previous week, Zai Lab had 9 more articles in the media than Zymeworks. MarketBeat recorded 17 mentions for Zai Lab and 8 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.45 beat Zai Lab's score of 0.75 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ZYME or ZLAB more profitable? Zai Lab has a net margin of -76.14% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Zai Lab's return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% Zai Lab -76.14%-36.97%-27.10% SummaryZymeworks beats Zai Lab on 15 of the 19 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$880.50M$6.72B$5.45B$18.71BDividend YieldN/A3.11%5.11%4.04%P/E Ratio-8.447.2722.3332.70Price / Sales11.54241.43397.0128.26Price / CashN/A65.8538.1817.53Price / Book1.916.356.714.47Net Income-$118.67M$143.17M$3.22B$1.02B7 Day Performance4.20%4.57%4.16%3.35%1 Month Performance2.43%-1.39%-0.87%-2.90%1 Year Performance52.11%-2.64%16.81%3.25% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks2.7759 of 5 stars$12.66-1.7%$21.00+65.9%+55.9%$880.50M$76.30M-8.44460Positive NewsZLABZai Lab2.1682 of 5 stars$29.71+3.0%$47.37+59.4%+103.8%$3.26B$398.99M-10.731,950Positive NewsAKROAkero Therapeutics3.7749 of 5 stars$37.67+0.1%$76.29+102.5%+113.6%$3.00BN/A-10.0530Insider TradeNews CoverageMRUSMerus3.4477 of 5 stars$43.23+0.4%$85.31+97.3%+0.5%$2.99B$36.13M-10.9437Upcoming EarningsAnalyst ForecastShort Interest ↓News CoveragePositive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0596 of 5 stars$29.81-3.1%$42.67+43.1%+118.0%$2.83B$33.19M-12.69140Upcoming EarningsNews CoveragePositive NewsPTGXProtagonist Therapeutics3.4439 of 5 stars$45.80-1.0%$65.44+42.9%+76.5%$2.81B$434.43M17.22120Upcoming EarningsPositive NewsCRNXCrinetics Pharmaceuticals3.6494 of 5 stars$30.15-0.9%$73.00+142.1%-21.4%$2.81B$1.04M-8.08210News CoveragePositive NewsSWTXSpringWorks Therapeutics2.8983 of 5 stars$37.06-2.3%$73.20+97.5%+1.4%$2.78B$191.59M-10.65230Upcoming EarningsAnalyst ForecastNews CoverageGap UpOGNOrganon & Co.4.7601 of 5 stars$10.67-4.0%$20.60+93.1%-31.4%$2.75B$6.40B3.2010,000Upcoming EarningsNews CoveragePositive NewsCPRXCatalyst Pharmaceuticals4.6746 of 5 stars$22.02-2.2%$32.29+46.6%+58.7%$2.69B$491.73M18.6680Upcoming EarningsPositive News Related Companies and Tools Related Companies ZLAB Alternatives AKRO Alternatives MRUS Alternatives MOR Alternatives SRRK Alternatives PTGX Alternatives CRNX Alternatives SWTX Alternatives OGN Alternatives CPRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZYME) was last updated on 4/29/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZYME Stock Free ZYME Stock Alerts